Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →
A Category 1 PLI Pharma applicant of the Alkem-scale complex-generics persona must reconstruct FY 2019-20 identified-product sales at SKU-and-UoM level for a 10-molecule approved product basket, convert the pre-GST-2.0 12 percent HSN 3004 output-invoice value to a net-of-tax equivalent (the actual revenue realised under Ind AS 115), standardise the tablet-capsule-vial dose form across the workbook, adjust for DPCO 2013 ceiling-price movement on NLEM-scheduled molecules, submit the base-sales register with the audited financial statements and the GSTR-1 and GSTR-3B FY 2019-20 returns to the Department of Pharmaceuticals Project Management Agency, and secure the DoP-approved base-year certificate that anchors every subsequent Year 1 through Year 6 incremental sales bridge on the quarterly claim workbook. Base-year sales illustratively at Rs 285 crore across the 10-molecule basket; Year 1 minimum incremental threshold of 10 percent = Rs 314 crore; Year 4 cumulative incremental sales approaching Rs 1,650 crore against a DoP-set Year 4 threshold of Rs 780 crore = 212 percent-of-threshold performance = raw incentive of Rs 165 crore capped at the Rs 100 crore Category 1 applicant-year cap. The base-year reconstruction is a five-to-six-year-old data-engineering exercise; SKU-level historical data recovery from the SAP or Oracle archive, UoM standardisation across dose forms, and volume-vs-value adjustment for MRP-controlled molecules under DPCO 2013 are the three surfaces where an untidy reconstruction breaks the DoP certification cycle.
Extract FY 2019-20 sales at invoice-line level from the SAP FI billing document archive or the Oracle Fusion sales invoicing history, filtered to identified products by ERP material-code mapping to the DoP-approved product list. For each invoice line, compute the net-of-tax revenue as gross invoice value divided by (1 + applicable output-tax rate) — 12 percent for most HSN 3004 formulation SKUs in FY 2019-20, 5 percent for the small subset. Sum invoice-line net revenue per SKU per state GSTIN per month across FY 2019-20 to produce the per-SKU monthly sales register. Apply the UoM standardisation table to convert primary pack UoM (10-tablet strip, 30-capsule bottle, 5-vial pack) to per-dose-form quantity so the workbook carries both value and standardised physical volume. Cross-check the aggregated FY 2019-20 sales value against the audited revenue line for identified products under Ind AS 115 and against the GSTR-1 outward supplies filed for FY 2019-20 across every state GSTIN. Net off Section 34 credit-note adjustments recorded post-year-end against FY 2019-20 invoices (returns, trade discount reconciliation, price protection). For NLEM-scheduled SKUs, tag each SKU with the FY 2019-20 NPPA ceiling price and set up the DPCO 2013 price-control adjustment register that will track ceiling-price movement across the six-year scheme window. Submit the reconciled base-sales register with the audited financial statements, the FY 2019-20 GSTR-1 and GSTR-3B returns, the ERP-to-DoP mapping table, the UoM standardisation table, the DPCO 2013 flag and ceiling-price snapshot, and the statutory auditor certificate to the DoP Project Management Agency for base-year certification. On issue of the DoP base-year certificate, freeze the base-sales register as the immutable reference for the Year 1 through Year 6 incremental sales bridge on the quarterly claim workbook.
SAP FI billing document extract (or Oracle Fusion sales invoicing history) for FY 2019-20 at invoice-line detail; ERP material master with DoP-approved identified-product flag and product-code mapping; UoM standardisation table with dose-form and per-unit conversion factors; HSN and tax-code map (HSN 3004 at 12 percent for most FY 2019-20 formulations, 5 percent for the small subset); NLEM-scheduled-formulation flag and NPPA ceiling-price snapshot for scheduled SKUs; Section 34 CGST credit-note register keyed to original FY 2019-20 invoices; state GSTIN roster for the applicant's multi-state manufacturing and invoicing footprint; audited financial statements FY 2019-20 (standalone entity); GSTR-1 and GSTR-3B FY 2019-20 filings; Ind AS 115 revenue recognition policy note; statutory auditor certificate template for base-year sales certification; DoP base-year certificate template and Project Management Agency submission pack format; DPCO 2013 price-control adjustment register with per-SKU ceiling-price movement tracker across the six-year scheme window; Year N incremental sales bridge template with volume-growth leg and price-realisation leg decomposition for scheduled formulations.
A DoP-submission-ready FY 2019-20 base-sales pack: the per-SKU per-molecule sales register at both value (net-of-tax revenue in rupees) and standardised physical volume, aggregated to the identified-product-basket total; the ERP-to-DoP product code mapping table with every SKU accounted for; the UoM standardisation table for cross-SKU comparability; the NLEM DPCO 2013 flag and FY 2019-20 NPPA ceiling-price snapshot for scheduled SKUs; the Section 34 credit-note net-off register; the state-GSTIN-level GSTR-1 and GSTR-3B FY 2019-20 tie-out; the Ind AS 115 revenue reconciliation to the audited standalone financial statements; and the statutory auditor certificate confirming the base-year sales value. On issue of the DoP base-year certificate, the frozen base-sales register anchors every Year 1 through Year 6 quarterly claim workbook — the Year N per-quarter identified-product sales extraction, the incremental sales bridge against the DoP-set year threshold, the Category 1 incentive at 10 percent (Years 1-4) / 8 percent (Year 5) / 6 percent (Year 6) with the Rs 100 crore applicant-year cap binding, and the DPCO 2013 volume-vs-value decomposition on scheduled formulations.
A Category 1 PLI Pharma applicant of the complex-generics scale of Alkem Laboratories — the Mumbai-headquartered integrated formulator operating manufacturing plants at Baddi in Himachal Pradesh, Daman, Ankleshwar in Gujarat, and Mandva — reconstructing FY 2019-20 product-level sales at UoM level for a Department of Pharmaceuticals PLI Category 1 application across an approved basket of ten complex-generic molecules faces the load-bearing data-engineering exercise of the scheme window. The pre-GST-2.0 12 percent HSN 3004 output invoice values must be converted to net-of-tax revenue; the tablet-capsule-vial dose forms must be standardised across the workbook for cross-SKU comparability; the DPCO 2013 ceiling-price movement on NLEM-scheduled molecules must be tracked; and the audited financial statements plus the GSTR-1 and GSTR-3B returns for FY 2019-20 must reconcile to the base-sales register before the DoP Project Management Agency will issue the base-year certificate. This is PLI pharma base year FY 2019-20 incremental sales reconciliation at operating scale for a Category 1 complex-generics applicant, and the discipline that lands the DoP base-year certificate cleanly on first pass — rather than through a four-to-six-week query-and-correction cycle — is what keeps the Year 1 through Year 6 quarterly claim workbook running on schedule.
Quick reference
| Aspect | Detail |
|---|---|
| Scheme administrator | Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers |
| Base year | FY 2019-20 (April 2019 to March 2020) |
| Base-year certifying body | DoP-nominated Project Management Agency (PMA) |
| Identified-product basket (illustrative) | 10 complex-generic molecules |
| Base-year sales (illustrative) | Rs 285 crore net-of-tax across the approved basket |
| FY 2019-20 GST output rate on HSN 3004 (most classes) | 12 percent |
| FY 2019-20 GST output rate on HSN 3004 (small subset) | 5 percent |
| Category 1 Year 1 minimum incremental requirement | 10 percent of base = Rs 314 cr threshold (illustrative) |
| Category 1 incentive rate — Years 1 to 4 | 10 percent of eligible incremental sales |
| Category 1 applicant-year cap | Rs 100 crore |
| DPCO 2013 scheduled-formulation authority | National Pharmaceutical Pricing Authority (NPPA) |
| Reconciliation entry point | SAP FI billing document extract or Oracle Fusion sales invoicing history |
| Base-year workbook submission pack | Register + audit statements + GSTR-1/3B + ERP mapping + UoM table + DPCO snapshot + auditor certificate |
The reconciliation in one paragraph
A Category 1 PLI Pharma applicant runs a four-surface reconstruction of FY 2019-20 identified-product sales before the Department of Pharmaceuticals will issue the base-year certificate. Surface one is the invoice-line extract from the SAP FI billing document archive or the Oracle Fusion sales invoicing history for FY 2019-20, filtered to identified products by ERP material-code mapping to the DoP-approved product list, with the net-of-tax revenue computed at each invoice line by dividing gross value by (1 plus the applicable output-tax rate) — 12 percent for most HSN 3004 formulations in FY 2019-20, 5 percent for the small subset. Surface two is the UoM standardisation across the mixed tablet-capsule-vial dose forms in the approved basket, with a conversion table that maps primary pack UoM (10-tablet strip, 30-capsule bottle, 5-vial pack) to per-dose-form physical quantity so the workbook carries both value and standardised volume. Surface three is the DPCO 2013 NLEM-scheduled-formulation flag and the FY 2019-20 NPPA ceiling-price snapshot for each scheduled SKU, which sets up the volume-vs-value bridge that decomposes every subsequent Year N incremental sales computation. Surface four is the tie-out — the reconciled base-sales register cross-checks to the audited standalone financial statements for FY 2019-20 under Ind AS 115, to the GSTR-1 outward supplies filed for every state GSTIN, to the GSTR-3B tax paid, and to the Section 34 credit-note register for post-year-end adjustments — and the statutory auditor certificate anchors the DoP submission pack. Each surface has its own control test and its own DoP Project Management Agency review lens.
What the scenario looks like in India — the illustrative Alkem-scale persona
Alkem Laboratories, one of the top-five Indian domestic pharmaceutical companies by revenue with a headquarters in Mumbai and manufacturing plants at Baddi in Himachal Pradesh (the excise-legacy formulation cluster), Daman, Ankleshwar in Gujarat, and Mandva, is a representative Category 1 PLI Pharma applicant for a complex-generics approved product basket. Alkem’s public product portfolio spans oral solid dosage forms (tablets, capsules) in cardiac and anti-diabetic therapy, sterile injectables from its Ankleshwar plant, and complex-formulation SKUs that fit the Category 1 identified-product definition of complex generics. The applicant persona in this article — a Tier 1 integrated formulator with a Category 1 PLI application covering ten complex-generic molecules, an FY 2019-20 base sales value across the approved basket illustratively at Rs 285 crore, and manufacturing operations spanning Baddi, Daman, Ankleshwar, and Mandva — is the reconciliation surface being described. The persona is illustrative; real PLI Pharma applicant lists, approved product baskets, and DoP-certified base-sales values are disclosed in aggregate by the Department of Pharmaceuticals and are not the subject of speculative recomputation here. The point of the persona is the base-year reconstruction discipline, not the identity of any specific real applicant.
The regional manufacturing geography maps to state GSTINs — Baddi to Himachal Pradesh (03), Daman to Union Territory (25), Ankleshwar to Gujarat (24), Mandva to Gujarat (24), Mumbai headquarters and corporate GSTIN to Maharashtra (27). A PLI Pharma applicant with a multi-state manufacturing and invoicing footprint must consolidate the identified-product sales across every state GSTIN into a single base-year workbook, and the GSTR-1 outward-supply tie-out must reconcile at each state’s GSTIN filing rather than only at the aggregate group level. The 10-molecule approved basket is invoiced from multiple state GSTINs depending on manufacturing plant, distribution channel, and customer master routing, and the base-sales register must expose the state-GSTIN-level decomposition to the DoP Project Management Agency review.
The regulatory overlay — DoP scheme guidelines, DPCO 2013, Ind AS 115, HSN 3004 12 percent
Four regulatory anchors govern the FY 2019-20 base-year reconstruction, and each maps to a specific reconciliation control point.
The PLI Pharma scheme guidelines notified by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers fix FY 2019-20 as the immutable base year for computation of incremental sales across the six-year window (FY 2020-21 through FY 2025-26). Base sales values are submitted at the identified-product level, supported by audited financial statements and GST returns for FY 2019-20, and are approved by the DoP through a nominated Project Management Agency (PMA). The DoP-approved base becomes the immutable reference for all subsequent incremental sales computations. The Category 1 incentive rate schedule — 10 percent of eligible incremental sales for Years 1 through 4, 8 percent in Year 5, 6 percent in Year 6, capped at Rs 100 crore per applicant per year — is applied against the incremental delta computed as Year N identified-product sales minus the DoP-approved FY 2019-20 base. The PLI Pharma Rs 15,000 crore eligibility and incremental sales cornerstone sets out the full scheme framework across Categories 1, 2, and 3; this article drills into the base-year reconstruction surface for Category 1.
The Drug Prices Control Order 2013, administered by the National Pharmaceutical Pricing Authority, empowers the NPPA to fix and revise ceiling prices for scheduled formulations listed in the National List of Essential Medicines. Ceiling price is fixed at the simple average of the maximum retail prices of all brands of the same molecule and strength having a market share of one percent or more of the total market turnover, plus a wholesaler and retailer margin. Non-scheduled formulations are subject to a maximum annual price increase of 10 percent under Paragraph 20 of DPCO 2013. For the FY 2019-20 base-year workbook, each identified-product SKU is tagged with the DPCO scheduling status (scheduled or non-scheduled), the FY 2019-20 NPPA ceiling price if scheduled, and the volume-vs-value decomposition template that will track ceiling-price movement across the six-year PLI window. A downward NPPA revision during the scheme window is a real risk — ceiling prices for specific molecules in specific therapeutic classes have been revised by 10 to 30 percent in past NPPA notifications — and the DPCO 2013 adjustment register is the control that prevents a Year N price cut from being wrongly counted as a volume contraction on the incremental sales bridge.
HSN Chapter 30 covers pharmaceutical products, and HSN 3004 (medicaments in measured doses or in forms or packings for retail sale) is the primary classification for formulation SKUs sold by a Category 1 complex-generics applicant. FY 2019-20 attracted a GST output rate of 12 percent on HSN 3004 for most therapeutic classes, with a small subset at 5 percent (specific listed items and certain therapeutic categories). The GST 2.0 (56th GST Council) transition to 5 percent on pharma output changes the output-tax treatment prospectively but does not alter the FY 2019-20 base-year sales value, which must be captured at the then-prevailing 12 percent rate and converted to a net-of-tax equivalent for base-sales computation. The mechanic and the API-vs-formulation classification split is elaborated in the API vs formulation HSN 2941 / 3003 / 3004 reconciliation guide.
Ind AS 115 (Revenue from Contracts with Customers) governs the applicant’s revenue recognition in FY 2019-20 and therefore the revenue-line figure in the audited standalone financial statements. Base-year sales value on the DoP workbook must reconcile to the identified-product portion of the FY 2019-20 revenue line under Ind AS 115, net of any variable consideration (trade discount, price protection) that was constrained at FY 2019-20 year-end and subsequently recognised in FY 2020-21 or later. Section 34 CGST Act 2017 governs the credit-note register that captures the post-year-end adjustments; a rigorous base-year workbook back-traces every FY 2020-21 credit note issued against an FY 2019-20 invoice and nets it against the base-year value before submission. The month-end control-point discipline is set out in Terra Insight’s reconciliation playbook monthly close pillar.
A worked example — an Alkem-scale Category 1 applicant reconstructing FY 2019-20 base sales
Illustrative — the following figures represent the operating pattern of a Category 1 PLI Pharma applicant of the scale of a Tier 1 integrated complex-generics formulator with plants across Baddi, Daman, Ankleshwar, and Mandva. Public disclosures do not reveal per-product DoP-approved base sales values or the SKU-and-UoM reconstruction workbooks; the numbers below are illustrative of the reconciliation surface, not a claim about any specific real applicant’s PLI position.
A Category 1 applicant enters the scheme with a ten-molecule approved product basket. The FY 2019-20 SKU-level extract from the SAP FI billing document archive returns aggregated identified-product gross-of-tax invoice value of Rs 320 crore across the ten molecules and all state GSTINs. Converting to net-of-tax at the FY 2019-20 rate mix (nine molecules at HSN 3004 12 percent, one molecule at the 5 percent subset with an FY 2019-20 net weighted rate at approximately 11.7 percent) gives an intermediate base-year value of Rs 286 crore. Section 34 credit notes issued in FY 2020-21 against FY 2019-20 invoices — trade discount reconciliation on the two largest hospital-tender contracts, product returns on the sterile injectable line — total Rs 1 crore net; the base-year value nets down to Rs 285 crore, which reconciles to the identified-product portion of the FY 2019-20 audited revenue line under Ind AS 115.
The UoM standardisation table for the ten-molecule basket:
| Molecule (illustrative) | Dose form | Primary pack UoM | Per-dose-form conversion |
|---|---|---|---|
| Complex-generic A | Tablet | 10-tablet strip | Divide by 10 |
| Complex-generic B | Tablet | 30-tablet bottle | Divide by 30 |
| Complex-generic C | Capsule | 10-capsule strip | Divide by 10 |
| Complex-generic D | Sterile injectable | 5-vial pack | Divide by 5 |
| Complex-generic E | Sterile injectable | 1-vial pack | No conversion |
| Complex-generic F | Ampoule | 10-ampoule pack | Divide by 10 |
| Complex-generic G | Metered inhalation | 200-dose canister | Divide by 200 |
| Complex-generic H | Topical | 30-gram tube | Divide by 30 |
| Complex-generic I | Tablet | 100-tablet hospital pack | Divide by 100 |
| Complex-generic J | Capsule | 60-capsule bottle | Divide by 60 |
The DPCO 2013 scheduling status: three of the ten molecules (A, D, F) are NLEM-scheduled with NPPA ceiling prices notified in FY 2019-20; seven are non-scheduled and subject to the Paragraph 20 maximum annual price increase of 10 percent. The FY 2019-20 NPPA ceiling-price snapshot for the three scheduled SKUs is captured with the DPCO 2013 adjustment register template ready for the Year 1 through Year 6 tracking.
The Year 1 (FY 2020-21) minimum incremental sales requirement for Category 1 is 10 percent of base = Rs 28.5 crore of incremental sales to establish continued scheme participation, taking Year 1 identified-product sales to Rs 314 crore or above. The applicant’s actual Year 1 sales are Rs 340 crore = 8 percent above the threshold and a 19 percent uplift over the FY 2019-20 base. Year 1 raw incentive at 10 percent of the Rs 55 crore incremental = Rs 5.5 crore, well below the Rs 100 crore Category 1 applicant-year cap. Cumulative Year 4 (FY 2023-24) identified-product sales approach Rs 1,935 crore; incremental of Rs 1,650 crore against the FY 2019-20 base of Rs 285 crore, against a DoP-published Year 4 threshold of Rs 780 crore (a 212 percent-of-threshold performance). Raw Year 4 incentive at 10 percent of Rs 1,650 crore = Rs 165 crore. The Category 1 applicant-year cap of Rs 100 crore binds; the eligible Year 4 incentive claim is Rs 100 crore and the Rs 65 crore excess walks away — it does not roll forward to Year 5 or backward to Year 3 unused capacity. The cap-binding discipline is set out in the PLI Pharma cornerstone and applies unchanged to this Alkem-scale complex-generics persona.
Common reconciliation breakages
Five breakages recur when a Category 1 applicant reconstructs FY 2019-20 base sales for the DoP Project Management Agency submission, and each maps to a specific control failure.
-
Gross-of-tax base-year value submitted instead of net-of-tax. The applicant extracts the FY 2019-20 SAP FI billing document at gross invoice value and submits without dividing by 1.12 (or 1.05 for the 5 percent subset). The DoP PMA review typically catches the over-statement at first pass — the audited revenue line under Ind AS 115 is net-of-tax and the mismatch is immediately visible in the tie-out — and returns the workbook with a correction request. The reconciliation discipline is that the base-year workbook computes net-of-tax at the invoice line, and the aggregation to per-SKU and per-molecule totals is done on the net-of-tax figure. Applicants that catch this at draft-workbook stage save four to six weeks on the DoP certification cycle.
-
ERP material-code to DoP identified-product mis-mapping. The applicant’s ERP material master carries SKU codes under a naming convention that has evolved between FY 2019-20 and the PLI submission year — some FY 2019-20 SKUs have been rationalised, some brand names have changed, some strength variants have been split. The DoP-approved identified-product list is at the molecule level and the ERP-to-DoP mapping table must accommodate the FY 2019-20 SKU-to-current-SKU history. Applicants that use the current-year ERP material master without the historical mapping miss FY 2019-20 SKUs that no longer exist in the live material master and under-state the base. Reconciliation discipline requires the mapping table to be built with the FY 2019-20 SAP or Oracle material master snapshot, not the current-year snapshot.
-
UoM inconsistency across the base-year workbook and the Year N incremental bridge. The applicant reconstructs the FY 2019-20 base at value (net-of-tax revenue), but the Year N per-quarter identified-product sales extract is done at physical volume, and the volume-vs-value bridge for DPCO 2013 scheduled formulations fails because the UoM basis is inconsistent between the base-year and the Year N workbook. Reconciliation discipline requires the UoM standardisation table to be built once at base-year reconstruction and applied identically to every Year N per-quarter workbook, with value and volume tracked in parallel.
-
DPCO 2013 ceiling-price movement missing from the base-year workbook. The applicant’s base-year workbook captures the FY 2019-20 realised price per scheduled SKU but does not set up the DPCO 2013 adjustment register for tracking NPPA ceiling-price movement across the six-year PLI window. When NPPA revises a ceiling price downward during the scheme window, the Year N per-unit realised price falls and the raw Year N sales value understates the true volume growth on that scheduled SKU. Reconciliation discipline requires the DPCO 2013 flag and the FY 2019-20 ceiling-price snapshot to be embedded in the base-year workbook from day one, with the per-year NPPA revision tracker ready to update as revisions are notified. The failure mode is captured in Terra Insight’s reconciliation failure-mode analysis for India methodology as a specific ceiling-price-drift control test.
-
State-GSTIN-level GSTR-1 tie-out missing from the DoP submission pack. The applicant submits the base-year workbook with the group-level aggregated identified-product sales value but without the state-GSTIN-level decomposition that ties out to each state’s GSTR-1 outward supplies for FY 2019-20. The DoP Project Management Agency review requires the state-level tie-out to confirm that no state’s identified-product invoicing is missing from the workbook — a state whose GSTR-1 shows identified-product HSN 3004 invoicing that is not reflected in the base-year workbook signals either a missing state extract or a misclassified invoice. Reconciliation discipline requires the base-year workbook to carry a state-GSTIN column and a per-state per-month GSTR-1 tie-out schedule as part of the submission pack.
How a reconciliation platform handles this
A purpose-built pharma reconciliation platform ingests the FY 2019-20 SAP FI billing document archive extract at invoice-line detail, the ERP material master snapshot as at 31 March 2020, the DoP-approved identified-product list with the ERP-to-DoP mapping table, the state-wise GSTR-1 and GSTR-3B FY 2019-20 filings, the DPCO 2013 NLEM scheduling status and NPPA ceiling-price snapshot, the Section 34 credit-note register for post-year-end adjustments, and the audited standalone financial statements — and produces the reconciled FY 2019-20 base-sales register with the net-of-tax revenue per SKU per molecule per state GSTIN per month, the UoM-standardised physical volume in parallel, the DPCO 2013 flag and ceiling-price snapshot for scheduled formulations, the state-GSTIN GSTR-1 tie-out schedule, and the statutory auditor certificate template ready for the DoP Project Management Agency submission pack. Match rate improvement of 51 to 88 percent on the SKU-level extraction and the state-GSTIN tie-out, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a Category 1 PLI Pharma applicant reconstructing base-year sales across a ten-molecule approved product basket and multi-state manufacturing footprint rather than a spreadsheet substitute.
Cross-cluster bridges and where to read next
The PLI Pharma base-year reconstruction discipline in this depth article sits alongside the scheme-level framework unpacked in the PLI Pharma Rs 15,000 crore eligibility and incremental sales cornerstone and the Category-differentiation walk-through in the Category 1 vs 2 vs 3 differential-treatment sibling article. The HSN classification split between formulation (HSN 3004) and API (HSN 2941 / 3003) that determines the base-year value composition is elaborated in the API vs formulation HSN 2941 / 3003 / 3004 reconciliation guide. The methodology framework for structuring the base-year reconstruction as a controlled reconciliation surface is set out in Terra Insight’s reconciliation playbook monthly close pillar; the failure-mode framing for the DPCO 2013 ceiling-price drift and the ERP-to-DoP mapping breakages is set out in the reconciliation failure-mode analysis for India methodology. The commercial pillar for the entire pharma sub-cluster is Pharma reconciliation software India; the broader authority is reconciliation software India.
The five FAQs below address the operational questions pharma controllers and PLI scheme compliance leads ask most often when reconstructing FY 2019-20 base sales for the DoP Project Management Agency submission.
Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →
- ▸ PLI Pharma Rs 15,000 crore scheme guidelines, Department of Pharmaceuticals — The scheme identifies FY 2019-20 as the base year for computation of incremental sales across the six-year window (FY 2020-21 through FY 2025-26). Base sales values are submitted at the identified-product level, supported by audited financial statements and GST returns for FY 2019-20, and are approved by the Department of Pharmaceuticals through a nominated Project Management Agency. The DoP-approved base becomes the immutable reference for all subsequent incremental sales computations. Category 1 (complex generics, patented drugs, cell and gene therapy, orphan drugs) attracts 10 percent of eligible incremental sales for Years 1 through 4, 8 percent in Year 5, and 6 percent in Year 6, capped at Rs 100 crore per applicant per year.
- ▸ Drug Prices Control Order 2013, National Pharmaceutical Pricing Authority — DPCO 2013 empowers the National Pharmaceutical Pricing Authority (NPPA) to fix and revise ceiling prices for scheduled formulations listed in the National List of Essential Medicines (NLEM). Ceiling price is fixed at the simple average of the maximum retail prices of all brands of the same molecule and strength having a market share of one percent or more of the total market turnover, plus a wholesaler and retailer margin. Non-scheduled formulations are subject to a maximum annual price increase of 10 percent under Paragraph 20. Any downward revision of the ceiling price during the six-year PLI window requires the applicant to adjust the volume-to-value bridge on the identified-product base-sales register.
- ▸ Ind AS 20, Accounting for Government Grants and Disclosure of Government Assistance — Government grants are recognised in profit or loss on a systematic basis over the periods in which the entity recognises as expenses the related costs. The PLI grant is a grant related to income; the receivable is recognised when the applicant has reasonable assurance of compliance with scheme conditions. Presentation choice: other income line vs net-of-related-expense. The base-year FY 2019-20 sales register does not itself trigger an Ind AS 20 entry — recognition begins from Year 1 (FY 2020-21) forward as incremental sales are earned and the DoP portal claim workbook is filed.
- ▸ HSN Chapter 30 and GST Council rate notifications — HSN 3004 covers medicaments in measured doses or in forms or packings for retail sale — the primary classification for formulation SKUs sold by Category 1 PLI Pharma applicants. Pre-GST-2.0 rate on HSN 3004 formulations was 12 percent for most therapeutic classes. The GST 2.0 (56th GST Council) transition to 5 percent on pharma output changes the output-tax treatment prospectively but does not alter the FY 2019-20 base-year sales value, which must be captured at the then-prevailing rate and converted to a net-of-tax equivalent for base-sales computation on the DoP claim workbook.
- ▸ CGST Act 2017 sections on invoice, HSN, and output tax — Section 31 (tax invoice) and Rule 46 (contents of tax invoice) govern the invoice-level record that anchors the FY 2019-20 sales register. Section 34 (credit and debit notes) governs post-invoice adjustments — trade discounts, price protection, returns — that must be netted against the base-year sales value before the identified-product base is finalised for DoP submission. HSN 3004 invoice-line extraction from the SAP FI billing document or Oracle Fusion sales invoice is the reconciliation entry point for the base-year reconstruction workbook.